

Unstained
GAHu-Alexa 647
Ab #12
Ab #11
Ab #10
Ab #9
Ab #8
Ab #7
Ab #6
Ab #5
Ab #4
Ab #3
Ab #2
Ab #1
Antibody Clone
0
10
20
30
40
50
60
70
80
90
Mean Fluorescence Intensity

Fig. 1A



Ab#6
Ab#26
Ab#25
Ab#24
Ab#23
Ab#22
Ab#21
Ab#20
Ab#19
Ab#18
Ab#17
Ab#16
Ab#15
Ab#14
Antibody Clone
0
10
20
30
40
50
60
70
80
90
Mean Fluorescence Intensity

Fig. 1B



Affinity
Resonance Change Units
Ab#6
K_D = 4 nM
Time [min]

Fig. 2A



Affinity
Resonance Change Units
Ab#3
K_D = 8 nM
Time [min]

Fig. 2B



Mean Fluorescence Intensity
70
60
50
40
30
20
10
0
0.000
0.025
0.050
0.075
0.100
0.125
Ab #6
Ab #6 Concentration [µM]

Fig. 2C



Mean Fluorescence Intensity
125
100
75
50
25
0
0.00
0.05
0.10
0.15
0.20
0.25
0.30
Ab #3
Ab #3 Concentration [µM]

Fig. 2D



EGFR
BSA
ErbB3
TGFα
RLU
200000
180000
160000
140000
120000
100000
80000
60000
40000
20000
0
Ab #6 [nM]
0
200
400
600
800
1000
1200

Fig. 3



Control: total ErbB 3 in 0% serum in absence of Ab #6
Ab #6
total ErbB3 pg/ml
6000
5000
4000
3000
2000
1000
0
-12
-11
-10
-9
-8
-7
-6
Ab #6 Log [M]

Fig. 4



Control
20nM Ab #6 IgG1 UNTREATED
Secondary Ab alone
20nM Ab #6 IgG1 TREATED
Counts
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4
FL4-Height

Fig. 5A



Control
20nM Ab #6 IgG2 UNTREATED
Secondary Ab alone
20nM Ab #6 IgG2 TREATED
Counts
100
80
60
40
20
0
10^0
10^1
10^2
10^3
10^4
FL4-Height

Fig. 5B



Cell surface ErbB3:
75%
100
80
60
40
20
0
Counts
0 hrs
10^0
10^1
10^2
10^3
10^4
Fl1-Height
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6A



Cell surface ErbB3:
38%
100
80
60
40
20
0
Counts
0.5 hrs Post Treatment
10^0
10^1
10^2
10^3
10^4
Fl1-Height
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6B



Cell surface ErbB3:
18%
Counts
100
80
60
40
20
0
2 hrs post treatment
10^0
10^1
10^2
10^3
10^4
FL1-Height
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6C



Cell surface ErbB3:
5%
Counts
100
80
60
40
20
0
24 hr post
treatment
10^0
10^1
10^2
10^3
10^4
FL1-Height
Control
+100 nM Ab #6 IgG1-Alexa 488 (Unquenched)
+100 nM Ab #6 IgG1-Alexa 488 +
25 µg/ml anti-Alexa 488 (Quenched)

Fig. 6D



ngErbB3/mg total protein
0
10
20
30
40
50
60
70
80
Antibody Clone
Ab #1 IgG1
Ab #1 IgG2
Ab #11 IgG2
Ab #13 IgG1
Ab #13 IgG2
Ab #6 IgG1
Ab #6 IgG2
PBS control

Fig. 7



Total ErbB3 ng/mg total protein
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
PBS Control
Ab #6 treated
Antibody Treatment

Fig. 8



Control: 0% serum in absence of Ab # 6
Ab #6
ATP [M]
3.5×10-6
2.5×10-6
1.5×10-6
-12
-11
-10
-9
-8
-7
-6
-5
Ab #6 Log[M]

Fig. 9



Control: 0% serum in absence of Ab # 6
Ab # 6
ATP [M]
2.6×10-6
2.5×10-6
2.4×10-6
2.3×10-6
2.2×10-6
2.1×10-6
2.0×10-6
1.9×10-6
1.8×10-6
1.7×10-6
1.6×10-6
1.5×10-6
1.4×10-6
1.3×10-6
-12
-11
-10
-9
-8
-7
-6
-5
Ab #6 Log[M]

Fig. 10



Control - 0% serum in absence of Ab # 6
Ab # 6
ATP [M]
8.5×10-6
8.0×10-6
7.5×10-6
7.0×10-6
6.5×10-6
6.0×10-6
5.5×10-6
5.0×10-6
-12
-11
-10
-9
-8
-7
-6
-5
Ab #6 log[M]

Fig. 11



0.12
0.10
0.08
0.06
0.04
0.02
0
pErbB3 ng/mg total protein
PBS Control
Ab #6 treated
Antibody Treatment

Fig. 12




Fig. 13A




Fig. 13B




Fig. 13C




Fig. 14A




Fig. 14B




Fig. 15A




Fig. 15B




Fig. 15C




Fig. 16A




Fig. 16B




Fig. 16C




Fig. 16D



ADRr (Ovarian Cancer)
PBS Control
Ab#6 30ug
Ab#6 300ug
Tumor Volume pi/6 (L x W²) in mm³
Days post initiation
0 5 10 14 19 24 28 33 38 42 47 52 56
0 20 40 60 80 100 120 140 160
*P<0.05
ug/ml Ab#6 in serum
0 100 200 300 400 500 600
PBS
Ab#6 30ug
Ab#6 300ug
Ab #6 Dose

Fig. 17A



Tumor Volume p1/6 (L x W²) in mm³
1800
1600
1400
1200
1000
800
600
400
200
0
Du145 (Prostate Cancer)
PBS Control
Ab#6 300ug
Ab#6 600ug
0 3 7 10 14 18 21 24 28 31 35 38 42 45 49 52 56 59 63 66
Days post initiation
*P<0.05
ug/ml Ab#6 in serum
900
800
700
600
500
400
300
200
100
0
PBS
AB#6 300ug
AB#6 600ug
Ab#6 Dose

Fig. 17B



OvCAR8 (Ovarian Cancer)
PBS Control
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Tumor Volume pi/6 (L x W²) in mm³
0
100
200
300
400
500
600
0 4 7 11 14 16 21 25 28 32 35 39 42 46 49 52 55 58 61
Days post initiation
*P<0.05
ug/ml Ab#6 in serum
0
200
400
600
800
1000
1200
1400
PBS
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Ab#6 Dose

Fig. 17C



COLO357 (Pancreatic Cancer)
PBS Control
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Tumor Volume p/6 (L x W²) in mm³
Days Post Initiation
*P<0.05
ug/ml Ab#6 in serum
PBS
Ab#6 300ug
Ab#6 600ug
Ab#6 1500ug
Ab#6 Dose

Fig. 17D




Fig. 18A




Fig. 18B




Fig. 19A




Fig. 19B



100
80
60
40
20
0
Counts
10^0
10^1
10^2
10^3
10^4
FL2-Height
Control
No HB-EGF
1 nM HB-EGF
10 nM HB-EGF
200 nM HB-EGF.
500 nM HB-EGF

Fig. 20

Ab # 6 VH amino acid sequence (SEQ ID NO:1)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSG
GWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYW
GQGTLVTVSS

Ab # 6 VL amino acid sequence (SEQ ID NO:2)
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRP
SGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL

Ab # 3 VH amino acid sequence (SEQ ID NO:3)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYNMRWVRQAPGKGLEWVSVIYPS
GGATRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYYYYGMDV
WGQGTLVTVSS

Ab # 3 VL amino acid sequence (SEQ ID NO:4)
QSVLTQPPSASGTPGQRVTISCSGSDSNIGRNYIYWYQQFPGTAPKLLIYRNNQRPS
GVPDRISGSKSGTSASLAISGLRSEDEAEYHCGTWDDSLSGPVFGGGTKLTVL

Ab # 14 VH amino acid sequence (SEQ ID NO:5)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYGMGWVRQAPGKGLEWVSYISPS
GGHTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLETGLLVDA
FDIWGQGTMVTVSS

Ab # 14 VL amino acid sequence (SEQ ID NO:6)
QYELTQPPSVSVYPGQTASITCSGDQLGSKFVSWYQQRPGQSPVLVMYKDKRRPS
EIPERFSGSNSGNTATLTISGTQAIDEADYYCQAWDSSTYVFGTGTKVTVL

Ab # 17 VH amino acid sequence (SEQ ID NO:35)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYGMGWVRQAPGKGLEWVSYISPS
GGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLNYYYGLDVW
GQGTTVTVSS

Ab # 17 VL amino acid sequence (SEQ ID NO:36)
QDIQMTQSPSSLSASVGDRITITCQASQDIGDSLNWYQQKPGKAPRLLIYDASNLE
TGVPPRFSGSGSGTDFTFTFRSLQPEDIATYFCQQSANAPFTFGPGTKVDIK

Ab # 19 VH amino acid sequence (SEQ ID NO:37)
EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYGMWWVRQAPGKGLEWVSYIGSS
GGPTYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGRGTPYYFDS
WGQGTLVTVSS

Ab # 19 VL amino acid sequence (SEQ ID NO:38)
QYELTQPASVSGSPGQSITISCTGTSSDIGRWNIVSWYQQHPGKAPKLMIYDVSNRPSGVSNRF
SGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL

Fig. 21A

Ab # 6 VH CDR1 (SEQ ID NO:7)
HYVMA

Ab # 6 VH CDR2 (SEQ ID NO:8)
SISSSGGWTLYADSVKG

Ab # 6 VH CDR3 (SEQ ID NO:9)
GLKMATIFDY

Ab # 6 VL CDR1 (SEQ ID NO:10)
TGTSSDVGSYNVVS

Ab # 6 VL CDR2 (SEQ ID NO:11)
EVSQRPS

Ab # 6 VL CDR3 (SEQ ID NO:12)
CSYAGSSIFVI

Ab # 3 VH CDR1 (SEQ ID NO:13)
AYNMR

Ab # 3 VH CDR2 (SEQ ID NO:14)
VIYPSGGATRYADSVKG

Ab # 3 VH CDR3 (SEQ ID NO:15)
GYYYYGMDV

Ab # 3 VL CDR1 (SEQ ID NO:16)
SGSDSNIGRNYIY

Ab # 3 VL CDR2 (SEQ ID NO:17)
RNNQRPS

Ab # 3 VL CDR3 (SEQ ID NO:18)
GTWDDSLSGPV

Fig. 21B

Ab # 14 VH CDR1 (SEQ ID NO:19)
AYGMG

Ab # 14 VH CDR2 (SEQ ID NO:20)
YISPSGGHTKYADSVKG

Ab # 14 VH CDR3 (SEQ ID NO:21)
VLETGLLVDAFDI

Ab # 14 VL CDR1 (SEQ ID NO:22)
SGDQLGSKFVS

Ab # 14 VL CDR2 (SEQ ID NO:23)
YKDKRRPS

Ab # 14 VL CDR3 (SEQ ID NO:24)
QAWDSSTYV

Ab # 17 VH CDR1 (SEQ ID NO:39)
WYGMG

Ab # 17 VH CDR2 (SEQ ID NO:40)
YISPSGGITVYADSVKG

Ab # 17 VH CDR3 (SEQ ID NO:41)
LNYYYGLDV

Ab # 17 VL CDR1 (SEQ ID NO:42)
QASQDIGDSLN

Ab # 17 VL CDR2 (SEQ ID NO:43)
DASNLET

Ab # 17 VL CDR3 (SEQ ID NO:44)
QQSANAPFT

Ab # 19 VH CDR1 (SEQ ID NO:45)
RYGMW

Ab # 19 VH CDR2 (SEQ ID NO:46)
YIGSSGGPTYYVDSVKG

Ab # 19 VH CDR3 (SEQ ID NO:47)
GRGTPYYFDS

Ab # 19 VL CDR1 (SEQ ID NO:48
TGTSSDIGRWNIVS

Ab # 19 VL CDR2 (SEQ ID NO:49)
DVSNRPS

Ab # 19 VL CDR3 (SEQ ID NO:50)
SSYTSSSTWV

Fig. 21C

Ab # 6 VH Codon Optimized Nucleic Acid Sequence (SEQ ID NO:25)

gaggtgcagctgctggagagcggcggagggctggtccagccaggcggcagcctgaggctgtcctgcgccgc
cagcggcttcaccttcagccactacgtgatggcctgggtgcggcaggccccaggcaagggcctggaatgggtg
tccagcatcagcagcagcggcggctggaccctgtacgccgacagcgtgaagggcaggttcaccatcagcagg
gacaacagcaagaacaccctgtacctgcagatgaacagcctgagggccgaggacaccgccgtgtactactgca
ccaggggcctgaagatggccaccatcttcgactactggggccagggcaccctggtgaccgtgagcagc

Ab # 6 VL Codon Optimized Nucleic Acid Sequence (SEQ ID NO:26)

cagtccgccctgacccagcccgccagcgtgagcggcagcccaggccagagcatcaccatcagctgcaccgg
caccagcagcgacgtgggcagctacaacgtggtgtcctggtatcagcagcaccccggcaaggcccccaagct
gatcatctacgaggtgtcccagaggcccagcggcgtgagcaacaggttcagcggcagcaagagcggcaacac
cgccagcctgaccatcagcggcctgcagaccgaggacgaggccgactactactgctgcagctacgccggcag
cagcatcttcgtgatcttcggcggagggaccaaggtgaccgtccta

Ab # 3 VH Codon Optimized Nucleic Acid Sequence (SEQ ID NO:27)

gaggtgcagctgctggaaagcggcggagggctggtgcagccaggcggcagcctgaggctgtcctgcgccgc
cagcggcttcaccttcagcgcctacaacatgagatgggtgcggcaggccccaggcaagggcctggaatgggt
gtccgtgatctaccccagcggcggagccaccagatacgccgacagcgtgaagggcaggttcaccatcagcag
ggacaacagcaagaacaccctgtacctgcagatgaacagcctgagggccgaggacaccgccgtgtactactg
cgccaggggctactactactacggcatggacgtgtggggccagggcaccctggtgaccgtgagcagc

Ab # 3 VL Codon Optimized Nucleic Acid Sequence (SEQ ID NO:28)

cagagcgtgctgacccagcccccaagcgccagcggcaccccaggccagagggtgaccatcagctgcagcgg
cagcgacagcaacatcggcaggaactacatctactggtatcagcagttccccggcaccgcccccaagctgctga
tctacaggaacaaccagaggcccagcggcgtgcccgacaggatcagcggcagcaagagcggcaccagcgc
cagcctggccatcagcggcctgagaagcgaggacgaggccgagtaccactgcggcacctgggacgacagcc
tgagcggcccagtgttcggcggagggaccaagctgaccgtccta

Fig. 22A

Ab # 14 VH Nucleic Acid Sequence (SEQ ID NO:29)

gaagttcaattgttagagtctggtggcggtcttgttcagcctggtggttctttacgtctttcttgcgctgcttccggattca
ctttctctgcttacggtatgggttgggttcgccaagctcctggtaaaggtttggagtgggtttcttatatctctccttctgg
tggccatactaagtatgctgactccgttaaaggtcgcttcactatctctagagacaactctaagaatactctctacttgc
agatgaacagcttaagggctgaggacacggccgtatattactgtgcgaaagtactggaaactggcttattggttgat
gcttttgatatctggggccaagggacaatggtcaccgtctcaagc

Ab # 14 VL Nucleic Acid Sequence (SEQ ID NO:30)

cagtacgaattgactcagccaccctcagtgtccgtgtacccaggacagacagccagcatcacctgctctggagat
caattggggagtaaatttgtttcctggtatcagcagaggccaggccagtcccctgtgttggtcatgtataaagataaa
aggcggccgtcagagatccctgagcgattctctggctccaactctgggaacacagccactctgaccatcagcggg
acccaggctatagatgaggctgactattattgtcaggcgtgggacagcagcacttatgtcttcggcactgggacca
aggtcaccgtccta

Ab # 6 VH Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:31)

gaagttcaattgttagagtctggtggcggtcttgttcagcctggtggttctttacgtctttcttgcgctgcttccggattca
ctttctctcattacgttatggcttgggttcgccaagctcctggtaaaggtttggagtgggtttcttctatctcttcttctggt
ggctggactctttatgctgactccgttaaaggtcgcttcactatctctagagacaactctaagaatactctctacttgca
gatgaacagcttaagggctgaggacacagccgtgtattactgtactagaggtctcaagatggctacaatttttgacta
ctggggccagggcaccctggtcaccgtctcaagc

Ab # 6 VL Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:32)

cagagcgctttgactcagcctgcctccgtgtctgggtctcctggacagtcgatcaccatctcctgcactggaaccag
cagtgatgttgggagttataatgttgtctcctggtaccaacaacacccaggcaaagccccccaaactcatcatttatga
ggtcagtcagcggccctcaggggtttctaatcgcttctctggctccaagtctggcaacacggcctccctgacaatct
ctgggctccagactgaggacgaggctgattattactgctgctcatatgcaggtagtagtattttcgtgatattcggcg
gagggaccaaggtgaccgtccta

Ab # 3 VH Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:33)

gaagttcaattgttagagtctggtggcggtcttgttcagcctggtggttctttacgtctttcttgcgctgcttccggattca
ctttctctgcttacaatatgcgttgggttcgccaagctcctggtaaaggtttggagtgggtttctgttatctatccttctgg
tggcgctactcgttatgctgactccgttaaaggtcgcttcactatctctagagacaactctaagaatactctctacttgc
agatgaacagcttaagggctgaggacacggccgtgtattactgtgcgagagggtactactactacggtatggacgt
ctggggccaaggcaccctggtcaccgtctcaagc

Ab # 3 VL Pre-Optimization Nucleic Acid Sequence (SEQ ID NO:34)

cagagcgtcttgactcagccaccctcagcgtctgggacccccgggcagagggtcaccatctcgtgttctggaagc
gactccaacatcggaagaaattatatatattggtaccagcaattcccaggaacggcccccaagctcctcatctatag
gaataatcagcggccctcaggggtccctgaccgaatctctggctccaagtctggcacctcagcctccctggccatc
agtgggctccggtccgaggatgaggctgagtatcactgtggaacatgggatgacagcctgagtggtccggtattc
ggcggagggactaagctgaccgtccta

Fig. 22B

Ab #6 VLb:

QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGK
APKLMIYEVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYY
CCSYAGSSIFVIFGGGTKVTVL (SEQ ID NO:51)

Ab #17 VK1b:

QDIQMTQSPSSLSASVGDRITITCQASQDIGDSLNWYQQKPGKA
PRLLIYDASNLETGVPPRFSGSGSGTDFTFTFRSLQPEDIATYFC
QQSANAPFTFGPGTKVDIR (SEQ ID NO:52)

Ab #19 VL2b:

QYELTQPASVSGSPGQSITISCTGTSSDIGRWNIVSWYQQHPGK
APKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYY
CSSYTSSSTVVFGGGTKLTVL (SEQ ID NO:53)

Fig. 23



MCF-7
T47D
Colo-357
VEGF FU
8000
7000
6000
5000
4000
3000
2000
1000
0
None(0%FBS-medium)
10nM HRG ECD
HRG+2u Ab#6
HRG+4uM Ab #6
HRG+8uM Ab #6
None(0%FBS-medium)
10nM HRG ECD
HRG+2uM Ab #6
HRG+4uM Ab #6
HRG+8uM Ab #6
None (0 %FBS-medium)
10nM HRG ECD
HRG+2uM Ab #6
HRG+4uM Ab #6
HRG+8uM Ab #6
Treatment

Fig. 24A



H1975
COLO357
OVCAR8
pg/ug VEGF
20.0
16.0
12.0
8.0
4.0
0.0
10.0
6.0
2.0
Control
Ab #6
Treatment

Fig. 24B



Cell Line
COLO357
H1975
OvCAR8
% Inhibition of VEGF
% Inhibition of pErbB3
0
10
20
30
40
50
60
70
80
90
40
50
60
70

Fig. 24C




Fig. 25




Fig. 26A




Fig. 26B




Fig. 26C




Fig. 27A




Fig. 27B




Fig. 28




Fig. 29A



Fig. 29B



ACHN
vehicle
Ab# 6 (300µg)
Erlotinib (25mpk)
Ab# 6 + Erlotinib
Tumor Volume (mm3)
600
500
400
300
200
100
0
0
3
6
10
13
17
20
24
27
Days

Fig. 30



DU145
vehicle
Taxol (20mpk)
Ab#6 (300µg)
Ab#6 + Taxol (20mpk)
Tumor Volume (mm3)
600
500
400
300
200
100
0
0
3
9
12
16
19
23
26
30
33
Days

Fig. 31




Fig. 32A




Fig. 32B



Monotherapy
Tumor Volume (mm3)
2500
2000
1500
1000
500
0
vehicle
Ab# 6
0
4
7
11
14
18
21
28
35
42
49
Days

Fig. 32C




Fig. 33A




Fig. 33B



SGP-1
Ab #6
A
CHO-ErbB3
WT
B
CHO-ErbB3
D93A
C
CHO-ErbB3
M101A
Counts
Alexa-647
FL1-Height
0
40
80
120
160
200
10^0
10^1
10^2
10^3
10^4

Fig. 34



SGP-1
Ab #6
D
CHO-ErbB3
L102A
Counts
200
160
120
80
40
0
10^0
10^1
10^2
10^3
10^4
Alexa-647
FL1-Height
E
CHO-ErbB3
Y104A

Fig. 34




Fig. 35A




Fig. 35B



1.50
1.25
1.00
0.75
0.50
0.25
0.00
ErbB3 MUT/WT
0.00
0.25
0.50
0.75
1.00
1.25
1.50
Protein A MUT/WT
M38
M27
M1
M28
M13
M17
M18
M15
M24
M22
M4
M16
M6
M10
M34

Fig. 36

V_H

	CDR1	SEQ ID NO:
Wild Type	H-Y-V-M-A	7
Consensus	Xaa-Y/F/W/H-V-M-A	60
Paratope	Xaa-Y/F/W/H-V-Xaa-Xaa	63
	CDR2	
Wild Type	S-I-S-S-S-G-G-W-T-L-Y-A-D-S-V-K-G	8
Consensus	S-I-Xaa-Xaa-Xaa-G-G-W-T/A-L-Y-A-D-S-V-K-G	61
Paratope	$(Xaa)_7$-W-T/A-L-$(Xaa)_7$	64
	CDR3	
Wild Type	G-L-K-M-A-T-I-F-D-Y	9
Consensus	G-L-Xaa-M-A-T-I-F-Xaa-Y	62
Paratope	Xaa-L-Xaa-M-Xaa-T-I-Xaa-Xaa-Xaa	65

V_L

	CDR1	
Wild Type	T-G-T-S-S-D-V-G-S-Y-N-V-V-S	10
Consensus	T-G-Xaa-Xaa-Xaa-D-V-G-Xaa-Y/F/W/H-Xaa-V-V-S	66
Paratope	$(Xaa)_5$-D-Xaa-Xaa-Xaa-Y/F/W/H-Xaa-V-Xaa-Xaa	69
	CDR2	
Wild Type	E-V-S-Q-R-P-S	11
Consensus	$(Xaa)_5$-P-S	67
Paratope	$(Xaa)_7$	70
	CDR3	
Wild Type	C-S-Y-A-G-S-S-I-F-V-I	12
Consensus	C-S-Y/F/W/H-A-G-Xaa-Xaa-Xaa-F-V-I	68
Paratope	Xaa-Xaa-Y/F/W/H-$(Xaa)_8$	71

Fig. 37A

V_H

	CDR1	SEQ ID NO:
Wild Type	H-Y-V-M-A	7
Consensus	Xaa-Y/F-V-M-A	75
Paratope	Xaa-Y/F-V-Xaa-Xaa	76
	CDR2	
Wild Type	S-I-S-S-S-G-G-W-T-L-Y-A-D-S-V-K-G	8
Consensus	S-I-Xaa-Xaa-Xaa-G-G-W-T/A-L-Y-A-D-S-V-K-G	61
Paratope	$(Xaa)_7$-W-T/A-L-$(Xaa)_7$	64
	CDR3	
Wild Type	G-L-K-M-A-T-I-F-D-Y	9
Consensus	G-L-Xaa-M-A-T-I-F-Xaa-Y	62
Paratope	Xaa-L-Xaa-M-Xaa-T-I-Xaa-Xaa-Xaa	65

V_L

	CDR1	
Wild Type	T-G-T-S-S-D-V-G-S-Y-N-V-V-S	10
Consensus	T-G-Xaa-Xaa-Xaa-D-V-G-Xaa-Y/F-Xaa-V-V-S	77
Paratope	$(Xaa)_5$-D-Xaa-Xaa-Xaa-Y/F-Xaa-V-Xaa-Xaa	78
	CDR2	
Wild Type	E-V-S-Q-R-P-S	11
Consensus	$(Xaa)_5$-P-S	67
Paratope	$(Xaa)_7$	70
	CDR3	
Wild Type	C-S-Y-A-G-S-S-I-F-V-I	12
Consensus	C-S-Y/F -A-G-Xaa-Xaa-Xaa-F-V-I	79
Paratope	Xaa-Xaa-Y/F-$(Xaa)_8$	80

Fig. 37B




Fig. 38A




Fig. 38B




Fig. 38C




Fig. 38D




Fig. 39